The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I, first-in-human trial of an oral VEGFR tyrosine kinase inhibitor (TKI) x-82 in patients (pts) with advanced solid tumors.
Kathleen N. Moore
No relevant relationships to disclose
Suzanne Fields Jones
No relevant relationships to disclose
Carla Kurkjian
No relevant relationships to disclose
Hendrik-Tobias Arkenau
No relevant relationships to disclose
Jeffrey R. Infante
No relevant relationships to disclose
Shubham Pant
No relevant relationships to disclose
Howard A. Burris
No relevant relationships to disclose
D. Scott McMeekin
No relevant relationships to disclose
Jay Gibbons
Employment or Leadership Position - Tyrogenex
Stock Ownership - Tyrogenex
Kimberly Harrow
Employment or Leadership Position - Tyrogenex
Stock Ownership - Tyrogenex
Chris Liang
Employment or Leadership Position - Tyrogenex
Stock Ownership - Tyrogenex
Sara Ramsey
No relevant relationships to disclose
Johanna C. Bendell
No relevant relationships to disclose